Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Immunexpress Pty Ltd. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these active matters are housed within 1 distinct art unit, which suggests a high degree of technological overlap or a focused filing strategy in a specific niche of biotechnology. Despite being in 1 distinct art unit, the applications are being reviewed by 2 distinct examiners, which could introduce different perspectives on similar subject matter.
The busiest examiner for the portfolio is SALMON, KATHERINE D, who is responsible for 1 pending office action. Given that there are 2 pending office actions and 2 distinct examiners, each examiner is handling exactly 1 pending office action. This distribution means that while the technical field is concentrated in 1 distinct art unit, the company must still navigate the individual nuances of 2 distinct examiners. Practitioners should be aware that arguments successful with one examiner in this 1 distinct art unit may not necessarily be received the same way by the other examiner involved in the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
| DAUNER, JOSEPH G | 1 | 57.0% | +35.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18410314 | COMPOSITIONS FOR DISTINGUISHING BETWEEN DIFFERENT CONDITIONS | DAUNER, JOSEPH G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18596338 | TRIAGE BIOMARKERS AND USE THEREFOR | SALMON, KATHERINE D | — |
| 18410314 | COMPOSITIONS FOR DISTINGUISHING BETWEEN DIFFERENT CONDITIONS | DAUNER, JOSEPH G | — |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18596338 | TRIAGE BIOMARKERS AND USE THEREFOR | SALMON, KATHERINE D | 1682 | §103 | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18410314 | COMPOSITIONS FOR DISTINGUISHING BETWEEN DIFFERENT CONDITIONS | DAUNER, JOSEPH G | 1682 | §103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunexpress Pty Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Katherine D Salmon has the most, with 1 of Immunexpress Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
